Celecoxib (Lexib)
Celecoxib
Ruby Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Ruby Pharmaceuticals (Pty) Ltd
- Registrations
- 2
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lexib 100 EACH CAPSULE CONTAINS CELECOXIB 100,0 mg | 100 | 54003954/3.1/0039 | Registered | S3 | None |
| Lexib 200 EACH CAPSULE CONTAINS CELECOXIB 200,0 mg | 200 | 54004054/3.1/0040 | Registered | S3 | None |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Celecoxib
S3: Celecoxib
Consolidated Schedules 06 July 2026, line 3304
Pharmacological class: Antirheumatics (anti-inflammatory agents). (class 3.1)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
4-[5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Drag to rotate. Structure from PubChem CID 2662.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.